Innoviva (INVA) Income from Non-Controlling Interests (2017 - 2022)

Innoviva's (INVA) quarterly Income from Non-Controlling Interests came in at -$36.2 million in Q3 2022, down 153.45% YoY from $67.7 million in Q3 2021, and down 277.06% on a QoQ basis from $20.4 million in Q2 2022.

Innoviva (INVA) Income from Non-Controlling Interests (2017 - 2022) Analysis & Trends

Innoviva (INVA) has 6 years of Income from Non-Controlling Interests data on file, last reported at -$36.2 million in Q3 2022.

  • Quarterly Income from Non-Controlling Interests fell 153.45% year-over-year to -$36.2 million in Q3 2022, while the trailing twelve-month figure through Sep 2023 was -$36.2 million (down 148.87% YoY) and the FY2022 annual result came in at $6.3 million, down 70.68% from the prior year.
  • Income from Non-Controlling Interests slipped to -$36.2 million in Q3 2022, from $20.4 million in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of $67.7 million in Q3 2021 to a low of -$36.2 million in Q3 2022.
  • A 5-year average of $12.5 million and a median of $12.7 million in 2019 frame the typical range for Income from Non-Controlling Interests.
  • Annual changes were most pronounced in 2018 — Income from Non-Controlling Interests jumped 4128.68% — and 2022, when it sank 153.45%.
  • Tracing INVA's Income from Non-Controlling Interests over 5 years: stood at $5.5 million in 2018, then surged by 118.39% to $11.9 million in 2019, then surged by 77.23% to $21.1 million in 2020, then soared by 220.55% to $67.7 million in 2021, then slumped by 153.45% to -$36.2 million in 2022.
  • The last three Income from Non-Controlling Interests figures came in at -$36.2 million (Q3 2022), $20.4 million (Q2 2022), and $22.1 million (Q1 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 63.60 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Innoviva 1.54 Bn 968.79 Mn 90.62 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2022 -36.18 Mn
Jun 30, 2022 20.43 Mn
Mar 31, 2022 22.09 Mn
Sep 30, 2021 67.68 Mn
Jun 30, 2021 21.90 Mn
Mar 31, 2021 15.57 Mn
Dec 31, 2020 21.11 Mn
Sep 30, 2020 13.40 Mn
Jun 30, 2020 21.38 Mn
Mar 31, 2020 13.52 Mn
Dec 31, 2019 11.91 Mn
Sep 30, 2019 7.24 Mn
Jun 30, 2019 8.32 Mn
Mar 31, 2019 6.23 Mn
Dec 31, 2018 5.46 Mn
Sep 30, 2018 3.08 Mn
Jun 30, 2018 1.99 Mn
Mar 31, 2018 749,000.00
Dec 31, 2017 129,000.00